Chile Menopause Drugs Market – Industry Trends and Forecast to 2029

Market Analysis and Insights: Chile Menopause Drugs Market  

Chile menopause drugs market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 3.9% in the forecast period of 2022 to 2029 and is expected to reach USD 16.62 million by 2029 from USD 12.35 million in 2021. The rise in ageing population among women in Chile and ongoing research and development for hormonal and non-hormonal therapy medications to cure menopause are likely to be the major drivers which propel the market growth in the forecast period.

Menopause is the time when women’s menstrual cycles end. It's diagnosed after women’s gone 12 months without a menstrual period. Menopause can happen in 40s or 50s. During menopause, a woman's body makes less hormones estrogen and progesterone. The lower hormone levels, results in beginning of menopause symptoms such as hot flashes, mood change, changes in sex drive, insomnia, dry skin and weight gain.

Women chooses to treat their symptoms of menopause with hormonal and non-hormonal therapies. The hormonal therapy medications are combination therapy of estrogen/progesterone/progestin hormone therapy, estrogen, progesterone, a cocktail of estrogen with progesterone drugs and medroxyprogesterone acetate used to boost hormone levels to relieve some of the symptoms of menopause. The progestin-only medicines are taken with estrogen-only medicines, to lower the chance of getting endometrial cancer in women who still have their uterus.

According to Population Reference Bureau, Chile has the 11.8% of elderly people (65+) in Latin America. The ageing population in Chile are due to rise in fertility and mortality rates. The shift causes an increase in demand for long-term care for older people, particularly those requiring help with activities of daily living. Menopause had started in women aged 49 years in Chile. In 2017, the data by the Instituto Nacional de Estadísticas, stated that In Chile, older adults represent 16.2% of the population, and in 30 years, one in four people will be over 60.

The hormone therapy (HT) is one of the initiatives by the government for treatment of menopausal symptoms. The government raises awareness or delivers initiatives for better health, reduced cost and safety for the treatment of menopause symptoms.

For instance,

• Ministry of Health, Chile, introduced Preventive Medicine Exam for the Elderly (EMPAM), promoting healthy aging of older population which determines each older adult is classified according to risk of losing functionality, and actions are implemented, clearly preventive, treatment or rehabilitative ensuring a good quality of life.

The drivers responsible for the growth of the Chile menopause drugs market are the increased research and development, rise in ageing population among women, rise in government organizations and funding in Chile, reimbursement and rise in product approvals. However, the factors that are expected to restrain the market are the rise in the cost of the menopause drugs, rise in product recall. Lack of awareness about knowledge of menopause in Chile and complexity in menopause.

• On the other hand, strategic initiatives by market players, rise in healthcare expenditure and use of dietary supplements may act as an opportunity for the growth of the Chile menopause drugs market. The need for skilled expertise and the regulatory approval may create challenges for the Chile menopause drugs market. There are recent developments related to the Chile menopause drugs market.

The Chile menopause drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.   

Chile Menopause Drugs Market Scope and Market Size

Chile menopause drugs market is categorized into seven segments stages, type, menopause symptoms, dosage forms, route of administration, end user and distribution channel.

• On the basis of stages, the Chile menopause drugs market is segmented into postmenopause, perimenopause, and menopause. In 2022, the postmenopause segment is expected to dominate the Chile menopause drugs market due to high therapeutic potential of the selected drug.
• On the basis of type, the Chile menopause drugs market is segmented into non-hormonal therapy and hormonal therapy. In 2022, the non- hormonal therapy segment is expected to dominate the Chile menopause drugs market due to ensure the drug target has potential therapeutic benefit, ease of administration of supplements and  increased awareness of post-menopausal issues among women.
• On the basis of menopause symptoms, the Chile menopause drugs market is segmented into vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, joint pain, depression, weight gain and others. In 2022, the vasomotor segment is expected to dominate the Chile menopause drugs market due to the increased demand for treatment of hot flashes and vaginal dryness, which occurs due to vasomotor symptoms, market players investing in research and development (R&D) and rise in disposable income.
• On the basis of dosage form, the Chile menopause drugs market is segmented into tablet, cream, patch/film, rings, gel, injection shot, spray, and others. In 2022, the tablets segment is expected to dominate the Chile menopause drugs market, owing to the increased preference of oral administration for treatment of hot flashes and dyspareunia, by middle aged women in Chile, rise in consciousness about the onset of menopausal symptoms and growth in retail of tablets.
• On the basis of route of administration, the Chile menopause drugs market is segmented into oral, parenteral, transdermal, vaginal, and others. In 2022, the oral segment is expected to dominate the Chile menopause drugs market, as most of the drugs offered by the companies and highly used by consumers are oral therefore this segment is predicted to dominate the market.
• On the basis of end user, the Chile menopause drugs market is segmented into hospitals, clinics, home healthcare, and others. In 2022, the hospitals segment is expected to dominate the Chile menopause drugs market due to rise in research and development of exosomes and support from government in funding in Chile for the development of menopause drugs and correct prescription and guidance delivered by gynaecologists for correct use of hormonal and non-hormonal therapy are predicted to dominate the market.
• On the basis of distribution channel, the Chile menopause drugs market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2022, the hospital pharmacy segment is expected to dominate the Chile menopause drugs market due increased interaction with certified prescribers and health professionals for use of anti-depressant and guaranteed payment, are predicted to dominate the market.

Chile Menopause Drugs Market Country Level Analysis

Chile menopause drugs market is categorized into seven segments stages, type, menopause symptoms, dosage forms, route of administration, end user and distribution channel.

• In 2022, Chile is dominating the market, due to rise in research and development for menopause drugs in the pharmaceutical companies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential of the Chile Menopause Drugs in Emerging Economies and the Strategic Initiatives by Market Players are Creating New Opportunities in the Chile Menopause Drugs Market

Chile menopause drugs market also provides you with detailed market analysis for every country growth in particular industry with wound debridement device sales, impact of advancement in the Chile menopause drugs and changes in regulatory scenarios with their support for the Chile menopause drugs market. The data is available for historic period 2012 to 2020.

Competitive Landscape and Chile Menopause Drugs Market Share Analysis

Chile menopause drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the Chile menopause drugs market.

The major companies providing the Chile menopause drugs are Abbott, GlaxoSmithKline plc, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, AbbVie Inc., SAVAL Pharmaceuticals, Tecnofarma S.A., SYNTHON, Laboratorios Maver, Knop Laboratories, Fresenius Kabi Chile, Megalabs Chile S.A, and ITF-LABOMED FARMACEUTICA LTDA. among others.

The strategic initiatives by market players along with research and development for hormonal and non-hormonal therapy for Chile menopause drugs is expected to increase the net revenue and sales of the menopause drugs.

For instance,

• Caltrate by Pfizer Inc., is used to treat conditions caused by low calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia or rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the Chile menopause drugs market which also provides the benefit for organisation to improve their offering for treatment products.

SKU-67512